GPC3 and cancer: BAY 3547926 (<sup>225</sup>Ac-GPC3) is an <sup>225</sup>Ac-labeled antibody-chelator conjugate (ACC) that delivers <sup>225</sup>Ac directly to GPC3-expressing cancer cells and is a potential first-in-class targeted α-therapy in advanced HCC.